SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across i ...

Core Insights - Senti Biosciences, Inc. is advancing its proprietary Gene Circuit platform for next-generation cell and gene therapies, participating in a Cell & Gene Live virtual event to discuss innovative cell therapy technologies [1][2][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing cell and gene therapies for incurable diseases, utilizing synthetic biology to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [6] Product Development - SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy designed to target CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while protecting healthy bone marrow cells [4] - The therapy includes an OR GATE for targeting cancer cells, a NOT GATE to protect healthy cells, and calibrated-release IL-15 to enhance cell persistence and activity [4] - Currently, Senti Bio is enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202, which may become a first-in-class allogeneic treatment for AML/MDS patients [4] Regulatory Designations - The FDA has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including AML [5]

Core Insights - Senti Biosciences, Inc. has completed enrollment in its Phase 1 clinical trial for SENTI-202, a first-in-class CAR NK cell therapy targeting CD33 and FLT3 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) [1][2][3] - The clinical data presented at the ASH 2025 Annual Meeting showed deep, minimal residual disease (MRD)-negative, durable complete remissions and a favorable safety profile [1][2] - The company is planning to advance SENTI-202 into a pivotal study for R/R AML and is evaluating potential expansions to newly diagnosed AML and pediatric AML, with discussions with the FDA expected in the first half of 2026 [1][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][8] - SENTI-202 is designed to selectively target and eliminate hematologic malignancies while sparing healthy bone marrow cells, featuring an OR GATE for activation and a NOT GATE for protection of healthy cells [5] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may facilitate an expedited development and review process [1][6]

Core Insights - Senti Biosciences, Inc. has been selected to present at the Healthcare Conference Taipei 2026, showcasing its Gene Circuit technology platform and strategic priorities [1][2][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company aims to create therapies that precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing control post-administration [4] Presentation Details - The presentation is scheduled for February 10, 2026, from 10:30 AM to 10:40 AM local time, and will last for eight minutes [2] - The focus will be on the Gene Circuit technology, pipeline progress, and opportunities for partnerships in investment, research and development, manufacturing, and clinical collaboration [2][3] Strategic Importance - The conference will gather global investors and strategic partners, providing a platform for Senti Bio to discuss potential collaborations aimed at advancing transformative therapeutic programs [3]

Core Insights - Senti Biosciences, Inc. announced participation in a Virtual Investor CEO Connect Segment, highlighting its advancements in cell and gene therapies using the Gene Circuit platform [2][3] Group 1: FDA Designation and Clinical Trials - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, a potential first-in-class CAR-NK investigational cell therapy for relapsed/refractory hematologic malignancies, including AML [3] - SENTI-202 previously received Orphan Drug Designation from the FDA in June [3] - New data from a multinational clinical trial involving 20 patients (18 with evaluable responses) for SENTI-202 was presented at the American Society of Hematology (ASH) Annual Meeting [3] Group 2: Company Overview and Technology - Senti Bio is focused on developing next-generation cell and gene therapies for incurable diseases, utilizing a synthetic biology platform to engineer Gene Circuits [4] - The Gene Circuits are designed to selectively kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for post-administration control [4] - The company's pipeline includes cell therapies targeting both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [4]

Core Insights - Senti Biosciences, Inc. is participating in the Biotech Showcase 2026, highlighting its focus on next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The panel presentation titled "Engineering the Future: Advances in Cell and Gene Therapies" will take place on January 13, 2026, at 8:00 AM PST [2] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to developing innovative cell and gene therapies for patients with incurable diseases [4] - The company utilizes a synthetic biology platform to engineer Gene Circuits aimed at precisely targeting and killing cancer cells while sparing healthy cells [4] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Industry Context - The Biotech Showcase serves as a significant investor and networking conference for biotechnology and life sciences companies, providing a platform for presenting to investors and pharmaceutical executives [3] - This event is recognized for setting the tone for the biotechnology sector in the upcoming year, featuring multiple tracks, plenary sessions, and networking opportunities [3]

Core Viewpoint - Senti Biosciences (SNTI.US) reported promising data from its Phase 1 trial of SENTI-202 in R/R AML, showing a total overall response rate of 50% and a complete response/hematologic response rate of 42%, with most patients achieving minimal residual disease negativity [1] Group 1 - Senti Biosciences opened with a gain of over 7%, reaching a price of $2.54 [1] - The updated data from the Phase 1 trial indicates a significant efficacy in treating R/R AML [1] - The company received Regenerative Medicine Advanced Therapy (RMAT) designation to advance to pivotal studies [1]

Core Viewpoint - Senti Biosciences reported promising data from its Phase 1 trial of SENTI-202 in R/R AML, leading to a significant stock price increase of over 7% [1] Group 1: Clinical Data - The trial showed a total overall response rate (ORR) of 50% [1] - The complete response/complete hematologic response (CR/CRh) rate was 42% [1] - Most patients demonstrated a durable response with minimal residual disease negativity (MRD-Negative) [1] Group 2: Regulatory Support - Senti Biosciences received Regenerative Medicine Advanced Therapy (RMAT) designation to advance the study to pivotal research [1]

Core Viewpoint - Senti Biosciences reported promising data from its Phase 1 trial of SENTI-202 in R/R AML, leading to a significant stock price increase of over 7% [1] Group 1: Clinical Data - The trial showed a total overall response rate (ORR) of 50% [1] - The complete response/complete hematologic response (CR/CRh) rate was reported at 42% [1] - Most patients demonstrated a durable response with minimal residual disease negativity (MRD-Negative) [1] Group 2: Regulatory Support - Senti Biosciences received Regenerative Medicine Advanced Therapy (RMAT) designation to advance the study to pivotal research [1]

Senti Biosciences Conference Call Summary Company Overview - **Company**: Senti Biosciences (NasdaqCM:SNTI) - **Focus**: Development of gene circuit-based therapies for cancer treatment, specifically targeting acute myeloid leukemia (AML) with Senti 202 Key Industry Insights - **Industry**: Oncology, specifically the treatment of relapsed refractory AML - **Current Treatment Landscape**: - Existing therapies yield low complete remission (CR) rates of 12%-25% and CR/CRh rates of 20%-35% [16][17] - Median overall survival for relapsed refractory AML patients is approximately five months [16] Core Points from the Call - **Senti 202 Overview**: - A first-in-class off-the-shelf logic-gated CAR-NK cell therapy targeting CD33 and FLT3 [8] - Achieved a 50% overall response rate and a 42% CR/CRh rate in a phase 1 trial with 20 heavily pretreated relapsed refractory AML patients [8][39] - 100% of complete remission patients were MRD negative, indicating significant clinical benefits [9][40] - **Mechanism of Action**: - Utilizes a logic-gated approach to selectively kill cancer cells while sparing healthy cells [6][7] - Incorporates an OR gate to recognize cancer targets and a NOT gate to protect healthy cells [6][11] - **Clinical Trial Results**: - Phase 1 trial demonstrated durable responses with a median duration of composite CR of 7.6 months [9][39] - High MRD negative rates correlate with better long-term outcomes [9][40] - Safety profile supports outpatient dosing, with most adverse events being low-grade and manageable [21][39] - **Regulatory Designations**: - Received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation, facilitating closer collaboration with the FDA [9][40] - **Market Potential**: - Addressable market for Senti 202 includes approximately 28,000 relapsed refractory AML patients in the U.S. and EU, with potential expansion into newly diagnosed AML and pediatric AML populations [13][14] Additional Important Insights - **Patient Population**: - The trial enrolled patients with multiple adverse risk characteristics, with a median age of 49 years and a history of multiple prior therapies [26][27] - Senti 202 is not restricted by mutation status, allowing it to benefit a broader range of patients [21] - **Future Directions**: - Plans to initiate pivotal studies in 2026, with ongoing discussions with the FDA regarding trial design [41][43] - Potential for expanding indications to include solid tumors and other hematological malignancies [45] - **Technology Platform**: - Senti's broader gene circuits platform includes various types of genetic circuits that enhance the efficacy and safety of cell and gene therapies [44][45] Conclusion - Senti 202 shows promising efficacy and safety in treating relapsed refractory AML, with a strong potential for market impact and future expansion into other indications. The innovative logic-gated approach may address significant unmet needs in oncology, particularly for patients with limited treatment options.